Earlier, the stock hit $24.25, making today the first time since July ... United Therapeutics (NASDAQ:UTHR) was one of the worst-performing Nasdaq stocks of the day, plunging 13.03% to $46.34 after the FDA rejected the company's lung …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UTHR at https://www.zacks.com/ap/UTHR Keywords: United Therapeutics, …
Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ: …
Mr. Michael Benkowitz is President, Chief Operating Officer of the Company. He joined United Therapeutics in 2011 as Executive Vice President, Organizational Development. In this role, he was responsible for most companywide …
Biotechnology company United Therapeutics Corporation (UTHR), Tuesday, reported a narrower loss for the ... Per-share data have been adjusted to reflect a two-for-one stock split effected on September 22, 2009. Total revenue grew to …
To get more information, click here: http://zlk.9nl.com/united-therapeutics-uthr. There is no cost or obligation to you. If …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
United Therapeutics (NASDAQ:UTHR) announced Wednesday that its drug intended to treat patients suffering from pulmonary arterial hypertension (PAH) failed to meet the primary goal of a phase three study, causing its stock to …
The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned "Outperform" rating by Oppenheimer on Thursday, December 15. The Pelicans outscored the …